



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Spotlight on Special Topics

### OBESITY, INFLAMMATION, AND OUTCOMES IN COVID-19

Moderated Poster Contributions

Saturday, May 15, 2021, 11:45 a.m.-11:55 a.m.

---

Session Title: Markers to Measure Mortality: Biomarkers, Inflammatory Markers and Other Markers of Outcomes in Patients with COVID-19 Infection

Abstract Category: 61. Spotlight on Special Topics: Coronavirus Disease (COVID-19)

Presentation Number: 1088-17

---

Authors: *Kishan Padalia, Patrick J. O'Hayer, Elizabeth Anderson, Michael Pan, Tariq Azam, Husam Shadid, Hannah Berlin, Chelsea Meloche, Rafeeq Feroze, Erinleigh Michaud, Christopher Laurius, Penelope Blakely, Abbas Bitar, Salim Hayek, University of Michigan, Ann Arbor, MI, USA*

**Background:** Obesity is a risk factor for severe coronavirus disease 2019 (COVID-19), but the mechanism remains unclear. We hypothesized that obesity, itself an inflammatory condition, increases risk of severe COVID-19 via augmentation of the acute inflammatory response seen in severe COVID-19.

**Methods:** We performed a multicenter observational study leveraging the Michigan Medicine COVID-19 Cohort (M<sub>2</sub>C<sub>2</sub>) to analyze the relationship between obesity defined by body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, inflammatory biomarkers, and clinical outcomes in patients hospitalized for COVID-19. The study population included 733 patients admitted between March 1st and May 31st, 2020.

**Results:** On admission, obese patients had higher levels of C-reactive protein (CRP,  $p=0.011$ ), lactate dehydrogenase (LDH,  $p<0.001$ ), and soluble urokinase-type plasminogen activator receptor (suPAR,  $p=0.005$ ) than overweight (25.0-29.9 kg/m<sup>2</sup>) and normal BMI (18.5-24.9 kg/m<sup>2</sup>) patients. There were positive correlations between BMI and CRP (0.124;  $p=0.001$ ), LDH (0.209;  $p<0.001$ ), and suPAR (0.133;  $p=0.001$ ) which remained significant even after controlling for age, sex, race, smoking, diabetes, hypertension, and renal function. There were no significant differences in or correlations with levels of ferritin, D-dimer, or interleukin 6. Controlling for the same covariates, obese patients had a 2.4-fold increase in intensive care unit admission ( $p=0.001$ ), 2.3-fold increase in mechanical ventilation ( $p=0.003$ ), and 2.3-fold increase in vasopressor use ( $p=0.006$ ) compared to normal BMI patients. Obese patients did not have a significant increase in in-hospital mortality or dialysis, but every 5 kg/m<sup>2</sup> increase in BMI corresponded with a 1.2-fold increase in both in-hospital mortality ( $p=0.028$ ) and dialysis ( $p=0.035$ ). Addition of inflammatory markers to the regression model attenuated the association of BMI with mortality and dialysis but not mechanical ventilation.

**Conclusion:** The association between obesity and poor clinical outcomes in patients with COVID-19 is only partially accounted for by inflammation. Further study is warranted to elucidate the pathophysiologic link between obesity and severe COVID-19.